Related Experiment Videos
G-CSF in an infant donor: a method of reducing harvest volume in bone marrow transplantation
A Pession1, F Locatelli, A Prete
1Clinica Pediatrica III, Università di Bologna, Italy.
Insights
Bone marrow transplantation (BMT) using G-CSF stimulated peripheral blood stem cells from a young sibling donor is safe and effective for high-risk acute lymphoblastic leukemia (ALL) patients. This approach reduces risks and costs associated with bone marrow donation.
Area of Science:
- Hematology
- Pediatric Oncology
- Transplantation Immunology
Background:
- High-risk acute lymphoblastic leukemia (ALL) in children presents significant treatment challenges.
- Bone marrow transplantation (BMT) is a crucial curative option for pediatric ALL.
- Donor age and body weight can complicate BMT procedures, particularly regarding cell yield.
Observation:
- A case report details a 4-year-old female with high-risk ALL in first complete remission (CR).
- The patient received a BMT from an 11-month-old matched sibling donor.
- The donor received granulocyte-colony stimulating factor (G-CSF) to mobilize peripheral blood stem cells.
Findings:
- The procedure was performed to obtain adequate mononuclear cells within a limited bone marrow volume.
- The treatment demonstrated an absence of toxicity.
- The BMT procedure showed efficacy, with a good quality of post-transplant clinical outcome.
Implications:
- This G-CSF stimulated BMT approach is feasible and useful for overcoming donor-related limitations (age/weight).
- The strategy can significantly reduce the risks associated with bone marrow donation.
- This method offers a notable reduction in bone marrow donation costs.
Abstract:
We report the case of a 4-year-old female with high-risk ALL in first CR who received a BMT from an 11-month-old matched sibling treated with G-CSF in order to obtain an adequate number of mononuclear cells in a limited volume of bone marrow. The absence of toxicity, efficacy of the procedure and quality of the post-transplant clinical outcome suggest such treatments are feasible and useful to overcome problems caused by donor age and/or body weight. In view of this experience we demonstrate how such an approach leads to a notable reduction in risks and in bone marrow donation costs.